Breast malignant, males, children - Features to report for breast carcinoma

Home Chapter Home Jobs Conferences Fellowships Books

Breast malignant, males, children

Miscellaneous

Features to report for breast carcinoma

Reviewer: Monika Roychowdhury, M.D. (see Reviewers page)
Revised: 18 November 2012, last major update August 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.

Editor’s note

Required features to report
=========================================================================

● Specimen type / procedure
● Lymph node sampling (specify)
● Specimen size (third dimension is not required)
● Laterality (if known)
● Tumor site (if known)
● Invasive tumor size (at least one dimension is required)
● Invasive tumor histologic type
● Invasive tumor grade (Nottingham modification of Bloom-Richardson), including tubule formation, nuclear pleomorphism and mitotic activity (should grade lobular carcinoma and colloid carcinoma, don’t need to grade medullary carcinoma)
● Note: if another grading system is used, must still specify mitotic count
● TNM staging
● Number of lymph nodes examined, number involved by tumor, maximal metastasis size and presence of extracapsular spread
● Margins (distance of invasive and in-situ tumor from closest margin, specify margin)

Optional features to report, but recommended
=========================================================================

● Angiolymphatic invasion (note: tumor in dermal lymphatics may be due to benign mechanical transport, Hum Pathol 2005;36:310)
● Perineural invasion
● Involvement of nipple, skin (epidermis or dermis) and chest wall
● Multifocality
● Presence of microcalcifications and correlation with mammography
● Correlation of other findings with mammography
● Extent of margin involvement (if positive)
● DCIS (particularly if no invasive carcinoma present): size, morphologic type (architectural pattern), nuclear grade (high, intermediate, low), presence of comedocarcinoma (necrosis) and % of carcinoma represented by DCIS (25% or more is “extensive”); also margin involvement (focal or diffuse and distance to margin), presence of microcalcifications (within DCIS or elsewhere) and correlate with mammographic findings
● For invasive carcinoma: % of cells staining for ER and PR and intensity of staining (weak, moderate, strong)
● For invasive carcinoma: HER2 staining (0/negative, 1+/weak, 2+/partial circumferential staining and 3+/strong circumferential staining visible at low power)
● Fibrocystic disease
● Presence of ADH, ALH or LCIS

Optional features to report
=========================================================================

● Fibrotic focus
● Presence of extensive tumor necrosis
● Host lymphocytic response (Am J Surg Pathol 2003;27:194)

Quality of reporting
=========================================================================

● Improved in Australia after guidelines were issued; synoptic reports are more complete (Pathology 2009;41:361)

Templates
=========================================================================

● Michigan Cancer Consortium

Micro images
=========================================================================

AFIP images:

DCIS close to inked margin DCIS with a positive margin

DCIS at (or a basement membrane away from) the inked margin

Additional references
=========================================================================

● Arch Pathol Lab Med 2000;124:1026, Association of Directors of Anatomic and Surgical Pathology (2004), Arch Pathol Lab Med 2009;133:15

End of Breast malignant, males, children > Miscellaneous > Features to report for breast carcinoma

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at [email protected] with any questions (click here for other contact information).